HDAC9 and pancreatic neoplasm: While the in vitro results revealed promising activity of PIs in pancreatic cancer cells, one initial clinical study with the PI marizomib in combination with vorinostat, a HDAC inhibitor, showed no clinical responses in patients with pancreatic cancer [106].